Our new study in JAMA, Journal of the American Medical Association shows that ulcerative colitis patients with HLA-DRB1*01:03 face a significantly higher risk of severe disease—more hospitalizations, surgeries, and steroid use.
42% of carriers require major IBD surgery within 3 years vs 9% of non-carriers.